



19th EADO CONGRESS

April 20th–22nd, 2023

ROME, ITALY

AUDITORIUM DELLA TECNICA

**FINAL
PROGRAM**

UPDATE 17/04/2023



ON-SITE CONGRESS WITH
ADDITIONAL VIRTUAL ACCESS
WWW.EADO2023.COM

CONTENT

Welcome Message	3
Congress at a Glance	4
Congress History	5
Congress Destination	6
Congress Venue	7
Floor Plan	8
Congress Faculty	12
Additional Speakers	14
General Information from A-Z	16
Congress Organization	21
Scientific Program at a Glance	22
Scientific Program	25
Thursday, April 20th, 2023	26
Friday, April 21st, 2023	36
Saturday, April 22nd, 2023	46
Satellite Symposia at a Glance	54
Satellite Symposia Program	55
Sponsors	60
Company Profiles	62
Future Meetings	74

WELCOME MESSAGE

Dear Colleagues,

We have the great pleasure to invite you to join us for the **19th EADO Congress** taking place as an on-site meeting with additional virtual access **from April 20–22, 2023** in the amazing city of Rome, Italy.

The European Association of Dermato-Oncology Congress is the largest conference in dermatology, there are no competing meetings in this field. **Over 1,000 participants** from Europe and around the world are expected to attend.

The meeting provides updated scientific and clinical achievements in a wide spectrum of **skin tumors including melanoma, keratinocyte carcinomas and rare malignant neoplasms**. **The world's leading experts** have been invited as speakers and will offer you the opportunity to gain a comprehensive insight into all areas of dermatology.

Rome, also known as *The Eternal City*, is one of the most attractive cities in the world and well connected by many airlines. The city offers a wealth of historical sites as well as impressive architecture with countless charming squares and fountains. The historic center is a UNESCO World Heritage Site. Important attractions such as the Colosseum, the independent Vatican State as well as the Altar of the Fatherland are world-renowned.

Looking forward to welcoming you online or in Rome in April 2023!



Prof. Dr. Ketty Peris
Rome, Italy
Congress President



Prof. Dr. Claus Garbe
Tuebingen, Germany
Congress President

CONGRESS AT A GLANCE

Congress Organizer

MEDCONCEPT 

MedConcept GmbH
Friedenstr. 58
15366 Neuenhagen bei Berlin
Germany
Phone: +49 (0) 334242689-30
Fax: +49 (0) 334242689-40
E-Mail: congress@eado2023.com

Congress Venue

Auditorium della Tecnica
Viale Umberto Tupini, 65
00144 Rome, Italy
<https://centrocongressi.confindustria.it/en/>

Congress Website and Virtual Platform

www.eado2023.com

Congress Format

On-Site Meeting with Additional Virtual Access

Congress Presidents

Ketty Peris, Rome, Italy
Claus Garbe, Tuebingen, Germany

Italian Scientific Committee

Paolo Ascierio, Naples, Italy
Maria Concetta Fagnoli, L'Aquila, Italy
Giovanni Pellacani, Rome, Italy
Pietro Quaglino, Torino, Italy
Iris Zalaudek, Trieste, Italy

European Scientific Committee

Petr Arenberger, Prague, Czech Republic
Veronique Bataille, London, UK
Bylaitė-Bučinskienė, Vilnius, Lithuania
Véronique Del Marmol, Brussels, Belgium
Brigitte Dréno, Nantes, France
Reinhard Dummer, Zurich, Switzerland
Ana-Maria Forsea, Bucharest, Romania
Jean-Jacques Grob, Marseille, France
Catherine Harwood, London, UK
Axel Hauschild, Kiel, Germany
Christoph Höller, Vienna, Austria
Lidija Kandolf, Belgrade, Serbia
Roland Kaufmann, Frankfurt, Germany
Nicole Kelleners-Smeets, Maastricht, The Netherlands
Aimilios Lallas, Thessaloniki, Greece
Céleste Lebbé, Paris, France
Josep Malvehy, Barcelona, Spain
David Moreno-Ramirez, Seville, Spain
Judit Oláh, Szeged, Hungary
Hubert Pehamberger, Vienna, Austria
Caroline Robert, Paris, France
Mirna Šitum, Zagreb, Croatia
Eggert Stockfleth, Bochum, Germany
Alexander Stratigos, Athens, Greece
Ricardo Vieira, Coimbra, Portugal
Georg Weinlich, Innsbruck, Austria

Poster Award Committee

Thomas Eigentler, Berlin, Germany
Caterina Longo, Reggio Emilia, Italy

Oral Communication Award Committee

Mauro Alaibac, Padova, Italy
Piergiacomo Calzavara-Pinton, Brescia, Italy

Expected Number of Participants

1,000

Congress Language

English




Past and Upcoming EADO Congresses

The EADO (European Association of Dermato-Oncology) is an independent non-profit organization dedicated to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. One mission of the EADO is to support and organize meetings dedicated to the presentation of new research findings, the exchange of information and education for its members in the field of dermato-oncology. The first EADO Congress was held 2001 in Vienna, Austria.



- 2001 – Vienna, Austria
- 2003 – Marseille, France
- 2006 – Rome, Italy
- 2008 – Marseille, France
- 2009 – Vienna, Austria
- 2010 – Athens, Greece
- 2011 – Nantes, France
- 2012 – Barcelona, Spain
- 2013 – Hamburg, Germany
- 2014 – Vilnius, Lithuania
- 2015 – Marseille, France
- 2016 – Vienna, Austria
- 2017 – Athens, Greece
- 2018 – Barcelona, Spain
- 2019 – Paris, France
- 2020 – Virtual Meeting
- 2021 – Virtual Meeting
- 2022 – Seville, Spain
- 2023 – Rome, Italy
- 2024 – Paris, France
- 2025 – Athens, Greece
- 2026 – Prague, Czech Republic
- 2027 – Barcelona, Spain
- 2028 – Vienna, Austria

www.eado.org



CONGRESS DESTINATION



As a historic World Heritage city, Rome is rich in architecture and art. From the captivating Vatican Museums to the Colosseum and the Galleria Borghese, Rome offers many attractions to visit. The challenge when visiting the city is most probably to decide what not to do.



Airports

Rome has two airports, Fiumicino (FCO) in the Southwest and Ciampino (CIA) in the Southeast. Fiumicino is Rome's main international airport.

»» TOP

Attractions in Rome

- › Colosseum and the Arch of Constantine
- › Vatican City
- › St Peter's Basilica
- › Roman Forum
- › Pantheon
- › Trevi Fountain
- › Catacombs
- › Villa Borghese





CONGRESS VENUE



The **Auditorium della Tecnica** is located inside the Palace of Confindustria in the heart of Rome's business district Eur. The Palace was designed in the late 60's while the interiors of the convention center have been designed 1974. The center was extensively renovated in 2016 and revives a prestigious space, reinterpreted and reintroduced into the range of quality architectural features of the modern city. The venue, located under the court's level, is a conference centre composed of a large foyer, 800 seats in the main meeting room, 16 rooms for meetings from 20 to 250 people, and two exhibition areas of 1200 sqm. It offers a full service, boasting technologically advanced solutions and excellent catering services.

CONGRESS VENUE FLOOR PLAN

Auditorium della Tecnica

Viale Umberto Tupini 65

00144 Rome, Italy


<https://centrocongressi.confindustria.it/en/>





Auditorium
della Tecnica


GROUND FLOOR



**CONGRESS
VENUE
FLOOR PLAN**



**Auditorium
della Tecnica
FIRST FLOOR**





Auditorium della Tecnica

THIRD FLOOR



CONGRESS FACULTY

A

Prof. Mauro Alaibac
Padova, Italy

Prof. Petr Arenberger
Prague, Czech Republic

Prof. Giuseppe Argenziano
Naples, Italy

Prof. Paolo Ascierio
Naples, Italy

B

Dr. Veronique Bataille
London, United Kingdom

Prof. Jürgen Becker
Essen, Germany

Prof. Carola Berking
Erlangen, Germany

Dr. Paolo Bossi
Brescia, Italy

Prof. Matilda Bylaitė-Bučinskienė
Vilnius, Lithuania

C

**Prof. Piergiacomo
Calzavara-Pinton**
Brescia, Italy

D

Dr. Alessandro Di Stefani
Rome, Italy

Prof. Veronique Del Marmol
Brussels, Belgium

Dr. Emi Dika
Bologna, Italy

Prof. Thomas Dirschka
Wuppertal, Germany

Prof. Brigitte Dréno
Nantes, France

Prof. Reinhard Dummer
Zurich, Switzerland

E

Prof. Thomas Eigentler
Berlin, Germany

F

Prof. Maria Concetta Fargnoli
L'Aquila, Italy

Prof. Nicola Fazio
Milan, Italy

Prof. Ana-Maria Forsea
Bucharest, Romania

G

Prof. Claus Garbe
Tuebingen, Germany

Prof. Emmanuella Guenova
Lausanne, Switzerland

Samantha Guild
Richmond, USA

H

Prof. Catherine Harwood
London, United Kingdom

Prof. Jessica Hassel
Heidelberg, Germany

Prof. Axel Hauschild
Kiel, Germany

Prof. Christoph Höller
Vienna, Austria

K

Prof. Lidija Kandolf
Belgrade, Serbia

Prof. Roland Kaufmann
Frankfurt, Germany

Dr. Nicole Kelleners-Smeets
Maastricht, The Netherlands

Prof. Harald Kittler
Vienna, Austria

L

Prof. Aimilios Lallas
Thessaloniki, Greece

Prof. Céleste Lebbé
Paris, France

Prof. Ulrike Leiter-Stöppke
Tuebingen, Germany

Prof. Georgina Long
Sydney, Australia

Assoc. Prof. Caterina Longo
Reggio Emilia, Italy

Prof. Paul Lorigan
Manchester, United Kingdom

Dr. Bohdan Lytvynenko
Kyiv, Ukraine

M

Prof. Josep Malvehy
Barcelona, Spain

Prof. Friedegund Meier
Dresden, Germany

Prof. Olivier Michielin
Lausanne, Switzerland

Dr. Michael R. Migden
Houston, USA

Prof. David Moreno-Ramirez
Seville, Spain

O

Prof. Judit Oláh
Szeged, Hungary

Prof. Pablo Luis Ortiz-Romero
Madrid, Spain

P

Dr. Vishal A. Patel
Washington DC, USA

Prof. Liz Patton
Edinburgh, United Kingdom

Prof. Giovanni Pellacani
Modena, Italy

Prof. Ketty Peris
Rome, Italy

Prof. Nicola Pimpinelli
Florence, Italy

Q

Dr. Pietro Quaglino
Turin, Italy

Dr. Paola Queirola
Milan, Italy

R

Dr. Simone Ribero
Turin, Italy

Prof. Caroline Robert
Paris, France

Prof. Pietro Rubegni
Siena, Italy

S

Prof. Julia Scarisbrick
Birmingham, United Kingdom

Prof. Dirk Schadendorf
Essen, Germany

Prof. Mirna Šitum
Zagreb, Croatia

Prof. Eggert Stockfleth
Bochum, Germany

Prof. Alexander Stratigos
Athens, Greece

Dr. Mariano Suppa
Brussels, Belgium

V

Dr. Ricardo Vieira
Coimbra, Portugal

W

Prof. Georg Weinlich
Innsbruck, Austria

Prof. Julia Welzel
Augsburg, Germany

Prof. David Whiteman
Brisbane, Australia

Z

Prof. Iris Zalaudek
Trieste, Italy

ADDITIONAL SPEAKER

A

PhD Andrew Aplin
Philadelphia, USA

Prof. Monika Arenbergerova
Prague, Czech Republic

B

Prof. Arianna Baggiolini
Bellinzona, Switzerland

Prof. Martine Bagot
Paris, France

Prof. Raymond L. Barnhill
Paris, France

Prof. Jan Nico Bouwes Bavinck
Leiden, The Netherlands

C

Prof. Franck Carbonnel
Paris, France

Dr. Cristina Carrera
Barcelona, Spain

Claudia Piazza Cidonio
Rome, Italy

Dr. Elisa Cinotti
Siena, Italy

D

Dr. Stella de Jong
Leiden, The Netherlands

E

Prof. Alexander Eggermont, PhD
Utrecht, The Netherlands

F

Dr. Martina Ferioli
Bologna, Italy

Prof. Carla Ferrándiz-Pulido
Barcelona, Spain

Monica Forchetta
Ladispoli, Italy

G

Prof. Christoffer Gebhardt
Hamburg, Germany

Prof. Jeffrey E. Gershenwald
Houston, USA

Prof. Pascale Guitera
Sydney, Australia

Dr. Girish Gupta
Edinburgh, United Kingdom

H

PhD Merete Haedersdal
Copenhagen, Denmark

Prof. Douglas Hanahan
Lausanne, Switzerland

Prof. Lucie Heinzerling
Munich, Germany

Dr. Markus V. Heppt
Erlangen, Germany

Prof. Angela Hong
Sydney, Australia

Dr. Martin Hufbauer
Cologne, Germany

K

Dr. Philip Kienzl
Vienna, Austria

L

Dr. Zsuzsanna Lengyel
Pécs, Hungary

M

Dr. Joanna Mangana
Zurich, Switzerland

Prof. Daniela Massi
Florence, Italy

Prof. Alexander Menzies
Sydney, Australia

Prof. Giuseppe Micali
Catania, Italy

Prof. Peter Mohr
Buxtehude, Germany

Dr. Klara Mosterd
Maastricht, The Netherlands

N

Dr. Mirjam Nägeli
Zurich, Switzerland

Dr. Paul Nathan
London, United Kingdom

O

Prof. Patrick A. Ott
Boston, USA

P

Dr. Javiera Pérez
Barcelona, Spain

Dr. Ines Pires da Silva
Sydney, Australia

Dr. Elsemieke Plasmeijer
Amsterdam, The Netherlands

Dr. Susana Puig
Barcelona, Spain

R

Dr. Agata Rembielak, PhD
Manchester, United Kingdom

Prof. Alexander Rösch
Essen, Germany

S

Prof. Philippe Saiag
Versailles, France

Prof. Mahtab Samimi
Tours, France

Dr. Onofre Sanmartín
Valencia, Spain

Dr. Sandra Schuh
Augsburg, Germany

Prof. Richard Scolyer
Sydney, Australia

Dr. Deniz Seckin
Ankara, Turkey

Prof. Raute Sunder-Plassmann
Vienna, Austria

T

PhD Luca Tagliaferri
Rome, Italy

Prof. Alpaslan Tasdogan
Essen, Germany

Prof. Franz Trautinger
Vienna, Austria

Inbal Tuval
Givatayim, Israel

U

Prof. Selma Ugurel
Essen, Germany

V

Prof. Vincenzo Valentini
Rome, Italy

Dr. Erika Varga
Szeged, Hungary

Prof. Maarten H. Vermeer
Leiden, The Netherlands

W

Prof. Jörg Wischhusen
Wuerzburg, Germany

GENERAL INFORMATION FROM A-Z

IMPORTANT DEADLINES

April 5, 2023	E-Poster upload deadline for regular submission
April 6, 2023	Late-breaking & trials in progress notification of acceptance
April 13, 2023	E-Poster upload deadline for late-breaking abstracts
October 22, 2023	End of on-demand service

Abstracts

All accepted abstracts (oral communications and e-posters) will be published in the Book of Abstracts which will be available for download on the congress website. Please note that all texts are reproduced directly as submitted by the authors.

Abstracts Awards

The EADO is pleased to offer the following awards for abstracts submitted for oral and poster presentation:

e-Poster Awards

The best e-Poster on display in each of the following 3 categories will be awarded with 500 € each and a free registration to the next EADO Congress.

- › Melanoma diagnosis & treatment
- › Non-Melanoma Skin Cancer diagnosis & treatment
- › Basic research, genetics and epidemiology of skin cancer

Poster Discussion: Oral Communication Award

The best oral presentation will be awarded with 500€ and a free registration to the next EADO Congress.

All prize-winning approved submissions will be selected by the Poster & Oral Communication Committee. The prizes will be awarded on Saturday, April 22 from 15:30–15:45 during the Closing Ceremony in Room 1 (Auditorium).

Badges

The name badge is the official congress identification document. Please wear your badge at all times in order to gain entry into the session rooms and exhibition area. Admission to the congress area will not be permitted without badge identification. Kindly note that for the reprinting of lost or forgotten badges, an administrative fee of 20 Euro will be charged.

Cancellation Policy

Cancellations must be received in writing to registrations@eado2023.com by February 20, 2023. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to registrations@eado2023.com.

Certificate of Attendance and CME Certificate

For the tracking of your attendance, please come to the **CME Desk** in the foyer on the Ground Floor **daily** and **scan your badge** when you arrive and leave the congress building. For virtual participants, the time of participation is automatically tracked.

To download the two certificates, you will receive an email a few days after the congress with a link to the official EACCME questionnaire. The questionnaire must be filled in. After that we will check your presence at the congress. Once verified, the certificates will be sent to you by email **approx. 2 weeks after the meeting**.

Cloakroom and Luggage

The cloakroom is located next to the registration desk on the ground floor, please refer to the floor plan for orientation. As storage space is limited, we recommend all guests to store their baggage at the hotel. Please note that the organizer and the congress venue will not accept any liability for any items left behind.

CME Credits

The 19th European Association of Dermato-Oncology (EADO) Congress, Rome, Italy, 20/04/2023-22/04/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 17 European CME credits (ECMEC@s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC@s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Congress Bag

Congress bags can be picked up at the registration desk. Each bag contains a copy of the Program at a Glance and other useful information.

Congress Program

Please note that there will be no printed program provided on-site for sustainability reasons. You may find the printed Program at a Glance in your congress bag. The full program can be viewed via the congress app or can be downloaded as a pdf from the congress website. All registered delegates will receive further information by email shortly before the congress. Delegates may also scan the QR code available at the Registration Desk using their iPhone or Android.

You can also download the app here:



Once you have downloaded the app, please enter the **event code: eado2023rome** as well as your personal credentials (username and PIN) which you will receive on April 17, 2023.

Congress Venue

Auditorium della Tecnica

Viale Umberto Tupini, 65

00144 Rome, Italy

<https://centrocongressi.confindustria.it/en/>

Exhibition

A commercial exhibition will run during the congress. Visit the onsite industrial exhibition to get in touch with exhibitors, colleagues, collaborators and friends. Don't forget to visit the additional virtual information provided by the sponsors via the virtual congress platform.

Exhibition Opening Hours

Thursday, April 20 07:30–18:30

Friday, April 21 07:30–18:45

Saturday, April 22 08:30–16:00

First Aid

In case of emergency, please go to the First Aid room which is located next to the registration desk.

The Italian number for the ambulance service is 118.

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect of health and travel insurance.

Language and Translation

The official language of the meeting is English. Simultaneous translation will not be provided.

Liability Disclaimer

In the unlikely occurrence that the congress must be cancelled or postponed due to circumstances beyond the control of the organizers (natural disasters, political, social or economic events or other unforeseen events beyond control), the organizers cannot be held liable for any costs incurred by the event attendee. The organizer will record images during the event. By virtue of attendance, attendees agree to the organizer's usage of these recordings on the website and for marketing.

Lost & Found

Please hand in all found items at the registration desk. A lost and found box will be provided there.

Lunches and Refreshments

Coffee breaks and lunch will be served in the exhibition area on the ground floor. Kindly note that it is not allowed to bring food into the Room 1 (Auditorium).

Parking Facilities

The venue has 30 own parking spaces free of charge, but they cannot be reserved. The address for the navigation system is Viale dell'Astronomia 30.

There are additional public parking lots around the building, some of which are metered. At the EUR Magalina train station (distance from the auditorium: 600 m) you will find a paid parking garage.

Photography, audio, video and mobile phone policy

Audio, photo and video recording by any device is strictly prohibited during all scientific sessions, unless prior permission is obtained from the congress organiser.

Program Changes

The organizer reserves the right to make changes to the event program at short notice if necessary.

This does not result in any reimbursement claims. Program changes will be announced during the congress.

Questions to Speakers

Wireless microphones will be at your disposal during the discussion period in all sessions. Delegates wishing to participate in the discussion periods should make their way to the nearest microphone placed in the aisles.

Registration

Registration is only possible by using the online portal on the congress website:

<https://eado2023.com/registration/individual-registration/>.

Category / Fee	Early Bird Fee On-Site Attendance until March 15, 2023	Regular & Onsite Fee On-Site Attendance from March 16, 2023	Virtual Attendance
EADO Member	400 €	600 €	400 €
Non-EADO Member	500 €	650 €	500 €
Resident*	200 €	240 €	200 €
Student*	100 €	150 €	100 €
Day Tickets	250 €	250 €	–

* The resident / student registration rate will be granted only after receipt of proof. The written proof of status (e.g. letter signed by the head of department confirming the status of the applicant / copy of student ID card) can be uploaded online during the registration process.

Method of payment:

Only credit cards (Visa, MasterCard, American Express) will be accepted. Bank transfers are only possible in exceptional cases for group bookings / hospitals. Please note that in payments by bank transfers, the bank charges must be paid by the delegate.

On-site registration fee covers:

- › Admission to on-site & virtual scientific sessions and satellite symposia
- › Admission to the on-site & virtual industrial exhibition
- › On-site coffee breaks
- › Congress bag
- › Opening ceremony
- › Certificate of attendance
- › Book of abstracts
- › Login to the on-demand area (session files will be available until October 22, 2023)

Virtual registration fee covers:

- › Admission to virtual streaming of scientific sessions and satellite symposia
- › Admission to virtual industrial exhibition
- › Virtual opening ceremony
- › Certificate of attendance
- › Book of abstracts
- › Login to the on-demand area (session files will be available until October 22, 2023)

Registration Desk

The registration desk is situated on the ground floor on the left-hand side.

Opening hours:

Wednesday, April 19	15:00–19:00
Thursday, April 20	07:30–19:00
Friday, April 21	07:30–19:00
Saturday, April 22	08:00–17:00

Smoking

Smoking is strictly forbidden within the congress center.

Social Networks



Stay tuned and connected and follow the conference on Instagram and Facebook.

Facebook: <https://www.facebook.com/eadomelanoma/>

Instagram: https://www.instagram.com/eado_melanoma/

Speaker Preview Room

A Speakers' Preview Room is provided for all speakers. The room is situated on the ground floor on the left-hand side just after you enter the Auditorium della Tecnica. All presentations must be downloaded in the Speakers' Preview Room beforehand, as the presentations will be sent directly to the meeting room through the internal computer network.

Opening hours:

Wednesday, April 19	16:00–18:00
Thursday, April 20	07:00–18:30
Friday, April 21	07:00–18:30
Saturday, April 22	08:00–16:00

The following facilities will be provided in the room: computers (Windows operating system) to review, alter and upload the presentations to the server and support by technical staff.

The presentations should be handed into the Speakers' Preview Room **at least two hours before the session**. Speakers with a presentation during the first time slot of the morning are kindly asked to hand in their presentation the day before. All speakers will be able to find their presentations easily on the preview monitor on the lectern in the corresponding session room.

Sustainability

Sustainability is more important today than ever before. We are working internally on increasing our sustainability efforts and would like to encourage all involved in the 19th EADO Congress to minimize their environmental and social impacts. Go Green – Acting today for tomorrow!

Ways to get involved:

Travel by train / by carbon offsetting your flights to Rome and encourage your colleagues to do the same

Use the recycling bins provided on-site

Recycle your name-badge in the bin provided at the registration desk

Recycle all brochures and promotional items not needed in the bin provided within the industrial exhibition

Use the public transportation system in Rome

Welcome Reception

All registered delegates are invited to join the welcome reception on **Thursday, April 20, 2023** from 18:30–19:30 which will be held within the registration area. The Welcome Reception is open to all registered delegates, sponsors and exhibitors.

Time Zone

Rome is in the Central European Time Zone which is 1 hour ahead of Greenwich Mean Time (GMT +1). Like most states in Europe, Rome observes daylight saving (summer time). On Sunday, 26 March 2023 time will be shifted forward by 1 hour (GMT+2).

Weather

In April, the temperatures during the day in Rome range between 17°C and 21°C. However, the daily average temperature for Rome during April is around 19°C, which is a great temperature for many tourists as it's warm but not overly hot.

Wi-Fi

Free Wi-fi will be available within the congress area. The login details are as following:

Network: EADO2023

Password: ROME2023

CONGRESS ORGANIZATION

MEDCONCEPT 

Gesellschaft für medizinische Projekte mbH
Friedenstr. 58
15366 Neuenhagen bei Berlin
Germany

Phone +49 (0)3342 – 42 68 930
Responsible Project Manager:
Mrs. Mirja Christ
Email: congress@eado2023.com
www.medconcept.org



Thursday, April 20th, 2023

	Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)	Room 3 (130 seats, Third Floor)	Room 4* (60 seats, First Floor)
08:00–10:45	Dermatoscopy Course Basics and what's new	Oncology Course Basic questions in oncology	New Imaging Techniques	Skin Care in Organ Transplant Patients Europe (SCOPE)
10:45–11:15	Coffee Break + Exhibition Visit + Poster Viewing			
11:15–11:30	Opening Ceremony			
11:30–12:00	Keynote Lecture 1 Sequential treatments in metastatic melanoma			
12:00–12:30	Keynote Lecture 2 Melanoma models for the next generation of therapies			
12:30–13:15	Lunch Break + Exhibition Visit + Guided Poster Tour 1**			
13:15–13:45	Keynote Lecture 3 Management of immune-related adverse events			
13:45–14:45	Satellite Symposium 1 Gold Sponsor			
14:45–15:30	Coffee Break + Exhibition Visit + Guided Poster Tour 2***			
15:30–16:30	Symposium 1 Controversies in NMSC	Symposium 2 Melanoma research	Symposium 3 Biopsies, margins and second excision	EADO Scientific Projects From knowledge gap to trial
16:30–17:30	Symposium 4 European guidelines for skin cancer and updates	Symposium 5 Surgery of non- melanoma skin cancer	Symposium 6 New diagnostic approa- ches in skin cancer	Patient Advocates
17:30–18:00		Satellite Symposium 2	Satellite Symposium 3	
18:00–18:30				
18:30–19:30	Welcome Reception – Registration & External Area			

* In Room 4, only the Satellite Symposia and Symposium 19 will be streamed.

** Melanoma: Epidemiology and others

*** Melanoma: Experimental research, surgery and systemic treatment

Friday, April 21st, 2023

	Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)	Room 3 (130 seats, Third Floor)	Room 4* (60 seats, First Floor)
08:00–09:00	Symposium 7 Adjuvant therapy of melanoma	Symposium 8 Management of actinic keratosis and field cancerization	Symposium 9 Cutaneous T-cell lymphoma: from diagnosis to treatment	Satellite Symposium 3a
09:00–09:30				
09:30–10:30	Symposium 10 Controversies in melanoma management	Symposium 11 Management of advanced non melanoma skin cancer	Symposium 12 Cutaneous B-cell lymphoma: from diagnosis to treatment	Poster Discussion – Oral Communication I Melanoma: epidemiology and others
10:30–11:00	Coffee Break + Exhibition Visit + Guided Poster Tour 3**			
11:00–12:00	Satellite Symposium 1 Platinum Sponsor			
12:00–12:30	Keynote Lecture 4 Predictive biomarkers in melanoma			
12:30–13:30	Satellite Symposium 2 Platinum Sponsor			
13:30–14:00	Keynote Lecture 5 Neoadjuvant therapy in melanoma			
14:00–14:30	Keynote Lecture 6 NMSC			
14:30–15:00	Lunch Bags + Coffee Break + Exhibition Visit + Guided Poster Tour 4***			
15:00–15:30	Satellite Symposium 4	Satellite Symposium 5	Satellite Symposium 6	Satellite Symposium 7
15:30–16:00	Satellite Symposium 4a			
16:00–17:30	Symposium 13 Melanocytic nevi: biology and management	Symposium 14 Uveal, mucosal and acral melanomas	Symposium 15 Management of non-cut- aneous immune related adverse events (irAE)	Poster Discussion – Oral Communication II Melanoma: experimen- tal research, surgery and systemic treatment
17:30–18:15	Satellite Symposium 8	Satellite Symposium 8a		
18:15–18:30				

* In Room 4, only the Satellite Symposia and Symposium 19 will be streamed.

** Actinic keratoses and rare skin tumors

*** Basal cell carcinoma and squamous cell carcinoma

Saturday, April 22nd, 2023

	Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)	Room 3 (130 seats, Third Floor)	Room 4* (60 seats, First Floor)
09:00–10:00	Symposium 16 Challenging cases in dermatoscopy	Symposium 17 Merkel cell carcinoma	Symposium 18 Management of melanoma brain metastasis	Symposium 19 The role of local therapies in the interdisciplinary management of keratinocyte skin cancers
10:00–11:00	Symposium 20 Systemic treatment of unresectable metastatic melanoma	Symposium 21 Intralesional therapy for non-melanoma skin cancers: past, present, and the future		Poster Discussion – Oral Communication III Basal cell carcinoma and squamous cell carcinoma
11:00–11:45	Coffee Break + Exhibition Visit + Poster Viewing			
11:45–12:15	Keynote Lecture 7 Cutaneous lymphomas			
12:15–12:45	Keynote Lecture 8 Primary prevention of skin cancer: what the world can learn from Australia			
12:45–13:30	Lunch Break + Exhibition Visit + Poster Viewing			
13:30–14:30	Symposium 22 Challenging cases in skin cancer			Poster Discussion – Oral Communication IV Actinic keratosis and rare skin tumors
14:30–15:30	Symposium 23 Management of easy-to-treat basal and squamous cell carcinoma	Symposium 24 Management of rare malignant skin tumors		
15:30–15:45	Closing Ceremony and Poster & Oral Communication Awards			

* In Room 4, only the Satellite Symposia and Symposium 19 will be streamed.




**SCIENTIFIC
PROGRAM**

Thursday, April 20th, 2023

Friday, April 21st, 2023

Saturday, April 22nd, 2023

Thursday, April 20th, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>08:00–10:45</p>	<p>08:00–10:45</p>
<p>Dermatoscopy Course Basics and what's new <i>Chairs: Harald Kittler, Vienna, Austria</i> <i>Pietro Rubegni, Siena, Italy</i></p>	<p>Oncology Course Basic questions in oncology <i>Chairs: Christoph Höller, Vienna, Austria</i> <i>Olivier Michielin, Lausanne, Switzerland</i></p>
<p>08:00–08:05 Welcome and introduction</p>	<p>08:00–08:05 Welcome and introduction <i>Christoph Höller, Vienna, Austria</i> <i>Olivier Michielin, Lausanne, Switzerland</i></p>
<p>Part 1: Basics 08:05–08:20 Benign versus malignant pigmented neoplasms <i>Iris Zalaudek, Trieste, Italy</i></p>	<p>08:05–08:25 Tumorigenesis and hallmarks of cancer <i>Doug Hanahan, Lausanne, Switzerland</i></p>
<p>08:25–08:40 Benign versus malignant non-pigmented neoplasms <i>Aimilios Lallas, Thessaloniki, Greece</i></p>	<p> Virtual Lecture 08:30–08:50 Principles of targeted therapies <i>Axel Hauschild, Kiel, Germany</i></p>
<p>08:45–09:00 Holistic approach: how to include contextual information beyond dermoscopy <i>Giuseppe Argenziano, Naples, Italy</i></p>	<p>09:00–09:20 Principles of immunotherapies <i>Caroline Robert, Paris, France</i></p>
<p>09:05–09:20 What's so special about special sites <i>Harald Kittler, Vienna, Austria</i></p>	<p>09:30–09:50 Resistance mechanisms <i>Christoph Höller, Vienna, Austria</i></p>
<p>Part 2: What's new 09:25–09:40 How machines will support dermoscopy in the future <i>Pietro Rubegni, Siena, Italy</i></p>	<p>10:00–10:20 Biomarkers for patient selection <i>Olivier Michielin, Lausanne, Switzerland</i></p>
<p>09:45–10:00 Total body imaging and sequential dermoscopy <i>Josep Malvehy, Barcelona, Spain</i></p>	<p>10:30–10:45 Discussion with expert panel, Q&A</p>
<p>10:05–10:20 Predicting invasion thickness, SLN-status and prognosis by dermoscopy <i>Susana Puig, Barcelona, Spain</i></p>	
<p>10:25–10:40 Combining dermoscopy and confocal microscopy <i>Caterina Longo, Reggio Emilia, Italy</i></p>	

Room 3 (130 seats, Third Floor)	Room 4 (60 seats, First Floor)
<p>08:00–10:45</p> <p>New Imaging Techniques <i>Chairs: Mariano Suppa, Brussels, Belgium Julia Welzel, Augsburg, Germany</i></p> <p>08:00–08:10 Introduction <i>Mariano Suppa, Brussels, Belgium Julia Welzel, Augsburg, Germany</i></p> <p>8:10–8:30 In vivo RCM <i>Giovanni Pellacani, Modena, Italy</i></p> <p>8:35–08:55 Ex vivo RCM <i>Javiera Pérez, Barcelona, Spain</i></p> <p>09:00–09:20 D-OCT <i>Sandra Schuh, Augsburg, Germany</i></p> <p>09:25–09:45 LC-OCT <i>Mariano Suppa, Brussels, Belgium</i></p> <p>09:50–10:10 New technologies: what is in the pipeline of innovation? <i>Pascale Guitera, Sydney, Australia</i></p> <p>10:10–10:45 Demonstration and measurements <i>All</i></p>	<p>08:00–10:45</p> <p>Skin Care in Organ Transplant Patients Europe (SCOPE) <i>Chairs: Carla Ferrandit-Pulido, Barcelona, Spain Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p> <p>08:00–08:05 Welcome and introduction <i>Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p> <p>08:05–08:20 Skin cancer following solid organ transplantation – the role of immunosuppression <i>Elsemieke Plasmeijer, Amsterdam, The Netherlands</i></p> <p>08:25–08:37 Prevention and treatment of cutaneous SCC by HPV vaccination <i>Martin Hufbauer, Cologne, Germany</i></p> <p>08:40–08:55 The ‘SCOPE-ITSCC metastases study’: transcrip- tome-based tumour stratification to better identi- fy cutaneous squamous cell carcinomas at risk for metastases in organ transplant recipients <i>Jan Nico Bouwes Bavinck, Leiden, The Netherlands</i></p> <p>09:00–09:15 Genetic risk factors for cutaneous squamous cell carcinomas in OTR <i>Raute Sunder-Plassmann, Vienna, Austria</i></p> <p> Virtual Lecture</p> <p>09:20–09:35 Actinic keratosis in transplant patients – an update <i>Markus V. Heppt, Erlangen, Germany</i></p> <p>09:40– 09:48 Comparative efficacy of checkpoint inhibitors versus other systemic treatments for advanced cutaneous squamous cell carcinoma in trans- plant patients <i>Carla Ferrandit-Pulido, Barcelona, Spain</i></p> <p style="text-align: right;"><i>see next page >>></i></p>

Thursday, April 20th, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)

Room 2 (250 seats, Third Floor)

10:45–11:15 Coffee Break + Exhibition Visit + Poster Viewing

Room 3 (130 seats, Third Floor)	Room 4 (60 seats, First Floor)
	<p>09:50–10:02 Comparative efficacy of checkpoint inhibitors versus other systemic treatments for advanced malignant melanoma in transplant patients <i>Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p> <p>10:05–10:17 Update on the position statement of SCOPE on the treatment of skin cancers with checkpoint inhibitors in transplant patients <i>Carla Ferrándiz-Pulido, Barcelona, Spain</i></p> <p>10:20–10:40 Tumour Board and expert panel discussion: difficult to treat cases <i>Chairs: Catherine Harwood, London, United Kingdom;</i> <i>Deniz Seckin, Ankara, Turkey</i> Case 1, Case 2 and Case 3 <i>Philip Kienzl, Vienna, Austria;</i> <i>Mirjam Nägeli, Zurich, Switzerland;</i> <i>Stella de Jong, Leiden, The Netherlands</i></p> <p>10:40–10:45 Closing remarks <i>Carla Ferrandit-Pulido, Barcelona, Spain</i> <i>Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p>

Thursday, April 20th, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
11:15–11:30 Opening Ceremony	
11:30–12:00	
Keynote Lecture 1 <i>Chair: Dirk Schadendorf, Essen, Germany</i> Sequential treatments in metastatic melanoma <i>Paolo Ascierto, Naples, Italy</i>	
12:00–12:30	
Keynote Lecture 2 <i>Chair: Brigitte Dréno, Nantes, France</i> Melanoma models for the next generation of therapies <i>Liz Patton, Edinburgh, United Kingdom</i>	
12:30–13:15 Lunch Break + Exhibition Visit + Guided Poster Tour 1: Melanoma: Epidemiology and others	
13:15–13:45	
Keynote Lecture 3 <i>Chair: Ketty Peris, Rome, Italy</i> Management of immune-related adverse events <i>Caroline Robert, Paris, France</i>	
13:45–14:45	
Satellite Symposium 1 Gold Sponsor <i>see separate satellite symposium program</i>	
14:45–15:30 Coffee Break + Exhibition Visit + Guided Poster Tour 2: Melanoma: Experimental research, surgery and systemic treatment	

Room 3 (130 seats, Third Floor)

Room 4 (60 seats, First Floor)

Thursday, April 20th, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>15:30–16:30</p>	<p>15:30–16:30</p>
<p>Symposium 1 Controversies in NMSC <i>Chairs: Paolo Bossi, Brescia, Italy</i> <i>Richard Scolyer, Sydney, Australia</i></p>	<p>Symposium 2 Melanoma research <i>Chairs: Reinhard Dummer, Zurich, Switzerland</i> <i>Dirk Schadendorf, Essen, Germany</i></p>
<p>DTT Classifications: Is it a progress?</p> <p>15:30–15:37 Yes: <i>Ketty Peris, Rome, Italy</i></p> <p>15:40–15:47 No: <i>Peter Mohr, Buxtehude, Germany</i></p> <p>Should we stop immunotherapy after achieving a complete response?</p> <p>15:50–15:57 Yes: <i>Paolo Bossi, Brescia, Italy</i></p> <p>16:00–16:07 No: <i>Ines Pires da Silva, Sydney, Australia</i></p> <p>Should every patient with basal cell and squamous cell carcinoma be treated?</p> <p>16:10–16:17 Yes: <i>Richard Scolyer, Sydney, Australia</i></p> <p>16:20–16:27 No: <i>Iris Zalaudek, Trieste, Italy</i></p>	<p>15:30–15:42 Developmental chromatin programs determine oncogenic competence in melanoma <i>Arianna Baggiolini, Bellinzona, Switzerland</i></p> <p>15:45–15:57 Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint <i>Jörg Wischhusen, Wuerzburg, Germany</i></p> <p>16:00–16:12 Tumor metabolism as therapeutic target? <i>Alpaslan Tasdogan, Essen, Germany</i></p> <p>16:15–16:27 Persister state-directed transitioning and vulnerability in melanoma <i>Alexander Rösch, Essen, Germany</i></p>

Room 3 (130 seats, Third Floor)	Room 4 (60 seats, First Floor)
<p>15:30–16:30</p> <p>Symposium 3 Biopsies, margins and second excision <i>Chairs: Alessandro Di Stefani, Rome, Italy</i> <i>Roland Kaufmann, Frankfurt, Germany</i></p> <p>15:30–15:42 Biopsies in skin cancer – practical aspects and modifications <i>Roland Kaufmann, Frankfurt, Germany</i></p> <p>15:45–15:57 All about excision margins – current and future role in skin cancer <i>Ricardo Vieira, Coimbra, Portugal</i></p> <p>16:00–16:12 Value of new imaging techniques in pre- and intra-operative margin control <i>Alessandro di Stefani, Rome, Italy</i></p> <p>16:15–16:27 Second excisions – when, why and how? <i>David Moreno-Ramirez, Seville, Spain</i></p>	<p>15:30–16:30</p> <p>EADO Scientific Projects From knowledge gap to trial <i>Chairs: Christoph Höller, Vienna, Austria</i> <i>Nicole Kelleners Smeets, Maastricht, The Netherlands</i></p> <p>15:30–15:35 Knowledge gaps in Melanoma Guideline <i>Claus Garbe, Tuebingen, Germany</i></p> <p>15:45–15:50 Knowledge gaps in Squamous Cell Carcinoma Guideline <i>Alexander Stratigos, Athens, Greece</i></p> <p>16:00–16:05 Knowledge gaps in Basal Cell Carcinoma Guideline <i>Maria Concetta Fagnoli, L'Aquila, Italy</i></p> <p>16:15–16:30 Funding of investigator initiated trials <i>Caroline Robert, Paris, France</i></p>

Thursday, April 20th, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>16:30–18:30</p>	<p>16:30–17:30</p>
<p>Symposium 4 European guidelines for skin cancer and updates <i>Chairs: Ketty Peris, Rome, Italy</i> <i>Alexander Stratigos, Athens, Greece</i></p>	<p>Symposium 5 Surgery of non-melanoma skin cancer <i>Chairs: David Moreno-Ramirez, Seville, Spain</i> <i>Ricardo Vieira, Coimbra, Portugal</i></p>
<p>16:30–16:45 Actinic keratosis guidelines <i>Lidija Kandolf, Belgrade, Serbia</i></p>	<p>16:30–16:40 Microscopically controlled surgery for basal cell carcinoma <i>Ricardo Vieira, Coimbra, Portugal</i></p>
<p>16:50–17:05 Squamous cell carcinoma guidelines <i>Alexander Stratigos, Athens, Greece</i></p>	<p>16:45–16:55 Microscopically controlled surgery for squamous cell carcinoma and other keratinocytic tumors <i>Onofre Sanmartín, Valencia, Spain</i></p>
<p>17:10–17:25 Basal cell carcinoma guidelines <i>Ketty Peris, Rome, Italy</i></p>	<p>17:00–17:10 Surgical approach to dermatofibrosarcoma protuberans and other rare skin tumors <i>David Moreno-Ramirez, Seville, Spain</i></p>
<p>17:30–17:45 Melanoma guidelines <i>Claus Garbe, Tuebingen, Germany</i></p>	<p>17:15–17:25 Destructive treatments of low-risk NMSC: when and how? <i>Roland Kaufmann, Frankfurt, Germany</i></p>
<p>17:50–18:05 Merkel cell carcinoma guidelines <i>Céleste Lebbé, Paris, France</i></p>	
<p>18:10–18:25 Dermatofibrosarcoma protuberans <i>Philippe Saiag, Versailles, France</i></p>	<p>17:30–18:00</p>
	<p>Satellite Symposium 2 <i>see separate satellite symposium program</i></p>
<p>18:30–19:30 Welcome Reception – Registration & External Area</p>	

Room 3 (130 seats, Third Floor)	Room 4 (60 seats, First Floor)
<p>16:30–17:30</p> <p>Symposium 6 New diagnostic approaches in skin cancer <i>Chairs: Veronique Del Marmol, Brussels, Belgium</i> <i>Giovanni Pellacani, Modena, Italy</i></p> <p>16:30–16:40 Advanced 2D and 3D total body scanning for detection of melanoma <i>Josep Malvehy, Barcelona, Spain</i></p> <p>16:45–16:55 Deep learning and noninvasive imaging to quantify keratinocyte atypia in a cancerization field <i>Veronique del Marmol, Brussels, Belgium</i></p> <p>17:00–17:10 Magnifying Dermoscopy (X400- x600): how far are we from histology? <i>Elisa Cinotti, Siena, Italy</i></p> <p>17:15–17:25 Non-invasive imaging and lentigo maligna surgery: where are we? <i>Javiera Perez, Barcelona, Spain</i></p>	<p>16:30–17:30</p> <p>Patient Advocates <i>Chair: Samantha Guild, Richmond, USA</i></p> <p>16:30–16:40 Advocates: Actively Supporting Patients <i>Samantha Guild, USA</i> <i>AIM at Melanoma</i></p> <p>16:45–16:55 Focus on the Patient <i>Claudia Piazza Cidonio, Italy</i> <i>Melanoma Italia ONLUS</i></p> <p>17:00–17:10 The Israeli National Skin Cancer Prevention Program <i>Inbal Tuval, Israel</i> <i>The Israeli Skin Cancer Association</i></p> <p>17:15–17:25 The importance of communication between doctor and patient for good therapeutic adherence in patients undergoing drug treatment <i>Monica Forchetta, Italy</i> <i>APaIM Italy</i></p>
<p>17:30–18:30</p> <p>Satellite Symposium 3 <i>see separate satellite symposium program</i></p>	

Friday, April 21st, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>08:00–09:30</p> <p>Symposium 7 Adjuvant therapy of melanoma <i>Chairs: Brigitte Dréno, Nantes, France</i> <i>Axel Hauschild, Kiel, Germany</i></p> <p>08:00–08:15 Adjuvant therapy in melanoma: a long story started 25 years ago <i>Alexander Eggermont, Utrecht, The Netherlands</i></p> <p>08:18–08:33 Today, can we cure patients with adjuvant therapies or just prolong DFS? <i>Axel Hauschild, Kiel, Germany</i></p> <p>08:36–08:51 Blood and tissue gene expression-profiling and implications for adjuvant therapy in melanoma <i>Susana Puig, Barcelona, Spain</i></p> <p>08:54–09:09 The concept of rechallenge with adjuvant therapy <i>Brigitte Dréno, Nantes, France</i></p> <p>09:12–09:27 What is the role of adjuvant radiotherapy in melanoma in the era of systemic therapy? <i>Alessandro Di Stefani, Rome, Italy</i></p>	<p>08:00–09:30</p> <p>Symposium 8 Management of actinic keratosis (AK) and field cancerization <i>Chairs: Thomas Dirschka, Wuppertal, Germany</i> <i>Nicole Kelleners-Smeets, Maastricht, The Netherlands</i></p> <p>08:00–08:15 Biology of AK <i>Nicole Kelleners-Smeets, Maastricht, The Netherlands</i></p> <p>08:18–08:33 Imaging technologies as diagnostic tools for AK <i>Giuseppe Micali, Catania, Italy</i></p> <p>08:36–08:51 Treatment update AK <i>Girish Gupta, Edinburgh, United Kingdom</i></p> <p>08:54–09:09 Treatment of the immunocompromised patient <i>Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p> <p>09:12–09:27 New approaches to study design in AK <i>Thomas Dirschka, Wuppertal, Germany</i></p>

Room 3 (130 seats, Third Floor)	Room 4 (60 seats, First Floor)
<p>08:00–09:30</p> <p>Symposium 9 Cutaneous T-cell lymphoma: from diagnosis to treatment <i>Chairs: Pablo Luis Ortiz-Romero, Madrid, Spain</i> <i>Pietro Quaglino, Turin, Italy</i></p> <p>08:00–08:12 What is new in cutaneous lymphoma <i>Pablo Luis Ortiz-Romero, Madrid, Spain</i></p> <p>08:15–08:27 MF/SS prognostic factors in real life: data from the PROCLIFI registry <i>Julia Scarisbrick, Birmingham, United Kingdom</i></p> <p>08:30–08:42 Detection of circulating tumour cells in CTCL <i>Maarten H. Vermeer, Leiden, The Netherlands</i></p> <p>08:45–08:57 EORTC CLG recommendations for MF/SS treatment <i>Franz Trautinger, Vienna, Austria</i></p> <p>09:00–09:12 New drugs and clinical trials <i>Martine Bagot, Paris, France</i></p> <p>09:15–09:27 Management of patients with CTCL in real life: old and new parameters for clinical and response evaluation <i>Pietro Quaglino, Turin, Italy</i></p>	<p>08:00–09:00</p> <p>Satellite Symposium 3a <i>see separate satellite symposium program</i></p>

Friday, April 21st, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>09:30–10:30</p> <p>Symposium 10 Controversies in melanoma management <i>Chairs: Paolo Ascierto, Naples, Italy</i> <i>Claus Garbe, Tuebingen, Germany</i></p> <p>Do we need a new melanoma classification?</p> <p>09:30–09:42 Yes: <i>Claus Garbe, Tuebingen, Germany</i></p> <p>09:45–09:57 No: <i>Jeffrey E. Gershenwald, Houston, USA</i></p> <p>Is adjuvant treatment of melanoma still needed?</p> <p>10:00–10:12 Yes: <i>Axel Hauschild, Kiel, Germany</i></p> <p>10:15–10:27 No: <i>Alexander Menzies, Sydney, Australia</i></p>	<p>09:30–10:30</p> <p>Symposium 11 Management of advanced non melanoma skin cancer <i>Chairs: Ulrike Leiter-Stöppke, Tuebingen, Germany</i> <i>Iris Zalaudek, Trieste, Italy</i></p> <p>09:30–09:42 Diagnostic of NMSC <i>Iris Zalaudek, Trieste, Italy</i></p> <p>09:45–09:57 Surgery and local treatment in advanced BCC and SCC <i>Roland Kaufmann, Frankfurt, Germany</i></p> <p>10:00–10:12 Systemic treatment in NMSC <i>Ulrike Leiter-Stöppke, Tuebingen, Germany</i></p> <p>10:15–10:27 New therapeutic approaches in refractory NMSC <i>Céleste Lebbé, Paris, France</i></p>

Room 3 (130 seats, Third Floor)	Room 4 (60 seats, First Floor)
<p>09:30–10:30</p> <p>Symposium 12 Cutaneous B-cell lymphoma: from diagnosis to treatment <i>Chairs: Nicola Pimpinelli, Florence, Italy</i> <i>Julia Scarisbrick, Birmingham, United Kingdom</i></p> <p>09:30–09:42 Classification and diagnosis of cutaneous B-cell lymphoma <i>Nicola Pimpinelli, Florence, Italy</i></p> <p>09:45–09:57 Staging of cutaneous B-cell lymphoma <i>Julia Scarisbrick, Birmingham, United Kingdom</i></p> <p>10:00–10:12 Prognostic factors in cutaneous B-cell lymphoma <i>Maarten H. Vermeer, Leiden, The Netherlands</i></p> <p>10:15–10:27 Treatment of cutaneous B-cell lymphoma <i>Pietro Quaglino, Turin, Italy</i></p>	<p>09:30–10:30</p> <p>Poster Discussion – Oral Communication I Melanoma: epidemiology and others <i>Chairs: Emi Dika, Bologna, Italy</i> <i>Georg Weinlich, Innsbruck, Austria</i></p> <p>09:30–09:38 Analysis of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: a case series <i>Iris Dirven, Brussels, Belgium</i></p> <p>09:40–09:48 Use of circulating extracellular vesicles and ctDNA from lymphatic fluid exudate as surrogate markers of minimal residual disease in melanoma patients <i>Maria Gonzalez-Cao, Barcelona, Spain</i></p> <p>09:50–09:58 One war and two battles of melanoma patients in Ukraine in 2022 <i>Mariia Kukushkina, Kiev, Ukraine</i></p> <p>10:00–10:08 Combined immunohistochemical expression of epidermal AMBRA1 and Loricrin as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I and II Melanoma: From discovery to validation <i>Penny Lovat, Newcastle, United Kingdom</i></p> <p>10:10–10:18 Prospective clinical trial with total body dermoscopy for the detection of melanocytic lesions with an autonomous scanner <i>Josep Malvehy, Barcelona, Spain</i></p> <p>10:20–10:28 Using a clinicopathologic and gene expression model to predict sentinel lymph node metastasis in primary cutaneous melanoma could reduce the rate of sentinel lymph node biopsies with >70%: a multicentre Danish cohort study <i>Marie Brinch-Møller Weitemeyer, Copenhagen, Denmark</i></p>

Friday, April 21st, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
10:30–11:00 Coffee Break + Exhibition Visit + Guided Poster Tour 3: Actinic keratoses and rare skin tumors	
11:00–12:00	
Satellite Symposium 1 Platinum Sponsor	
12:00–12:30	
Keynote Lecture 4 <i>Chair: Claus Garbe, Tuebingen, Germany</i> Predictive biomarkers in melanoma <i>Reinhard Dummer, Zurich, Switzerland</i>	
12:30–13:30	
Satellite Symposium 2 Platinum Sponsor	
13:30–14:00	
Keynote Lecture 5 <i>Chair: Axel Hauschild, Kiel, Germany</i> Neoadjuvant therapy in melanoma <i>Georgina Long, Sydney, Australia</i>	
14:00–14:30	
Keynote Lecture 6 <i>Chair: Caterina Longo, Reggio Emilia, Italy</i> NMSC <i>Iris Zalaudek, Trieste, Italy</i>	
14:30–15:00 Lunch Bags + Coffee Break + Exhibition Visit + Guided Poster Tour 4: Basal cell carcinoma and squamous cell carcinoma	
15:00–15:30	15:00–16:00
Satellite Symposium 4 <i>see separate satellite symposium program</i>	Satellite Symposium 5 <i>see separate satellite symposium program</i>
15:30–16:00	
Satellite Symposium 4a <i>see separate satellite symposium program</i>	

Room 3 (130 seats, Third Floor)

Room 4 (60 seats, First Floor)

15:00–16:00

Satellite Symposium 6
see separate satellite symposium program

15:00–15:45

Satellite Symposium 7
see separate satellite symposium program

Friday, April 21st, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>16:00–17:30</p> <p>Symposium 13 Melanocytic nevi: biology and management <i>Chairs: Veronique Bataille, London, United Kingdom</i> <i>Aimilios Lallas, Thessaloniki, Greece</i></p>	<p>16:00–17:30</p> <p>Symposium 14 Uveal, mucosal and acral melanomas <i>Chairs: Carola Berking, Erlangen, Germany</i> <i>Lidija Kandolf, Belgrade, Serbia</i></p>
<p>16:00–16:15 Atypical nevi: not just a skin phenotype <i>Veronique Bataille, London, United Kingdom</i></p>	<p>16:00–16:12 Treatment landscape of uveal melanoma <i>Carola Berking, Erlangen, Germany</i></p>
<p>16:18–16:33 Atypical nevi and early melanoma: balancing between under- and over-diagnosis <i>Raymond L. Barnhill, Paris, France</i></p>	<p>16:15–16:27 Tebentafusp – long-term experience in uveal melanoma <i>Paul Nathan, London, United Kingdom</i></p>
<p>16:36–16:51 Diagnosis and management of atypical Spitz tumors <i>Daniela Massi, Florence, Italy</i></p>	<p>16:30–16:42 New molecular targets in uveal melanoma <i>Andrew Aplin, Philadelphia, USA</i></p>
<p>16:54–17:09 Updated management recommendations for congenital nevi <i>Cristina Carrera, Barcelona, Spain</i></p>	<p>16:45–16:57 Treatment landscape of acral and mucosal melanoma <i>Lidija Kandolf, Belgrade, Serbia</i></p>
<p>17:12–17:27 Clinical management of individuals with a high nevus count <i>Aimilios Lallas, Thessaloniki, Greece</i></p>	<p> Virtual Lecture 17:00–17:12 New molecular targets in acral and mucosal melanoma <i>Markus Heppt, Erlangen, Germany</i></p>
	<p>17:15–17:27 Liquid biopsy in rare melanoma subtypes <i>Christoffer Gebhardt, Hamburg, Germany</i></p>

Room 3 (130 seats, Third Floor)	Room 4 (60 seats, First Floor)
<p>16:00–17:30</p> <p>Symposium 15 Management of non-cutaneous immune related adverse events (irAE) <i>Chairs: Lucie Heinzerling, Munich, Germany</i> <i>Paola Queirolo, Milan, Italy</i></p> <p> Virtual Lecture 16:00–16:15 Management of gastro-intestinal irAE <i>Franck Carbonnel, Paris, France</i></p> <p>16:18–16:33 Management of liver toxicity <i>Céleste Lebbé, Paris, France</i></p> <p>16:36–16:51 Management of endocrinopathy <i>Paola Queirolo, Milan, Italy</i></p> <p>16:54–17:09 Management of cardiac toxicity and myositis <i>Lucie Heinzerling, Munich, Germany</i></p> <p>17:12–17:27 Management of neurological toxicity <i>Jessica Hassel, Heidelberg, Germany</i></p>	<p>16:00–17:30</p> <p>Poster Discussion – Oral Communication II Melanoma: experimental research, surgery and systemic treatment <i>Chairs: Simone Ribero, Turin, Italy</i> <i>Eggert Stockfleth, Bochum, Germany</i></p> <p>16:00–16:08 Multimomics analysis of immune-related adverse events in melanoma patients treated with anti-PD1-based immune checkpoint inhibitors <i>Florentia Dimitriou, Zurich, Switzerland</i></p> <p>16:10–16:18 Identification of miRNA-gene networks affecting melanoma plasticity in response to immunotherapy <i>Katerina Grafanaki, Patras, Greece</i></p> <p>16:20–16:28 Targeting tropomyosin receptor kinases induces DNA damage and apoptosis via NGFR-ROS signaling in cutaneous melanoma <i>Maria Mannino, Milan, Italy</i></p> <p>16:30–16:38 A phase 3 trial comparing fiantlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) to pembrolizumab in patients with completely resected high-risk melanoma <i>Timothy Panella, Knoxville, USA</i></p> <p>16:40–16:48 Obesity and immune-checkpoint inhibitors in advanced melanoma: a meta-analysis of survival outcomes from clinical studies <i>Gabriele Rocuzzo, Turin, Italy</i></p> <p>16:50–16:58 Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma <i>Dirk Schadendorf, Essen, Germany</i></p>

Friday, April 21st, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>17:30–18:30</p> <p>Satellite Symposium 8 <i>see separate satellite symposium program</i></p>	<p>17:30–18:15</p> <p>Satellite Symposium 8a <i>see separate satellite symposium program</i></p>

Room 3 (130 seats, Third Floor)

Room 4 (60 seats, First Floor)

17:00–17:08

Long-term follow-up and subgroup analyses of metastatic melanoma patients treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Inge Marie Svane, Herlev, Denmark

17:10–17:18

First-in-human intratumoral administration of ASO1B in combination with autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and IV nivolumab in patients with refractory advanced melanoma

Jens Tjtgat, Brussels, Belgium

17:20–17:28

Association of miR-146a-5p and miR-21-5p with prognostic features in melanoma subtypes

Federico Venturi, Bologna, Italy

Saturday, April 22nd, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>09:00–10:00</p> <p>Symposium 16 Challenging cases in dermatoscopy <i>Chairs: Giuseppe Argenziano, Naples, Italy</i> <i>Josep Malvehy, Barcelona, Spain</i></p> <p>09:00–09:12 Challenging patients with multiple nevi <i>Josep Malvehy, Barcelona, Spain</i></p> <p>09:15–09:27 Challenging rashes <i>Aimilios Lallas, Thessaloniki, Greece</i></p> <p>09:30–09:42 Challenging pediatric lesions <i>Susana Puig, Barcelona, Spain</i></p> <p>09:45–09:57 Challenging non melanocytic lesions <i>Giuseppe Argenziano, Naples, Italy</i></p>	<p>09:00–10:00</p> <p>Symposium 17 Merkel cell carcinoma <i>Chairs: Nicola Fazio, Milan, Italy</i> <i>Jürgen Becker, Essen, Germany</i></p> <p>09:00–09:12 MCC biology and immunobiology – insights by single cell and spatial transcriptomics <i>Jürgen Becker, Essen, Germany</i></p> <p>09:15–09:27 Nodal MCC with unknown primary site and no distant metastasis: a challenging entity <i>Nicola Fazio, Milan, Italy</i></p> <p>09:30–09:42 Immunotherapy of early and advanced MCC <i>Paolo Ascierto, Naples, Italy</i></p> <p>09:45–09:57 Salvage therapies for MCC refractory to PD1/PD-L1 blockade <i>Selma Ugurel, Essen, Germany</i></p>

Room 3 (130 seats, Third Floor)	Room 4 (60 seats, First Floor)
<p>09:00–10:00</p> <p>Symposium 18 Management of melanoma brain metastasis <i>Chairs: Friedegund Meier, Dresden, Germany</i> <i>Jessica Hassel, Heidelberg, Germany</i></p> <p>09:00–09:12 Challenges of treating melanoma brain metastases <i>Philippe Saiag, Versailles, France</i></p> <p>09:15–09:27 Sequencing radiation and immunotherapy <i>Jessica Hassel, Heidelberg, Germany</i></p> <p>09:30–09:42 BRAFmut melanoma brain metastases: Triple or sequence? <i>Joanna Mangana, Zurich, Switzerland</i></p> <p>09:45–09:57 Emerging systemic treatment perspectives on brain metastases <i>Friedegund Meier, Dresden, Germany</i></p>	<p>09:00–10:00</p> <p>Symposium 19 The role of local therapies in the interdisciplinary management of keratinocyte skin cancers <i>Chairs: Ketty Peris, Rome, Italy</i> <i>Vincenzo Valentini, Rome, Italy</i></p> <p>09:00–09:12 Exclusive radiation therapy <i>Luca Tagliaferri, Rome, Italy</i></p> <p>09:15–09:27 Adjuvant radiation therapy <i>Agata Rembielak, Manchester, United Kingdom</i></p> <p>09:30–09:42 Electrochemotherapy <i>Martina Ferioli, Bologna, Italy</i></p> <p>09:45–09:57 New developments in radiation therapy <i>Angela Hong, Sydney, Australia</i></p>

Saturday, April 22nd, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>10:00–11:00</p>	<p>10:00–11:00</p>
<p>Symposium 20 Systemic treatment of unresectable metastatic melanoma <i>Chairs: Thomas Eigentler, Berlin, Germany</i> <i>Paul Lorigan, Manchester, United Kingdom</i></p>	<p>Symposium 21 Intralesional therapy for non-melanoma skin cancers: past, present, and the future <i>Chairs: Roland Kaufmann, Frankfurt, Germany</i> <i>Michael R. Migden, Houston, USA</i></p>
<p>10:00–10:15 What's new in classical checkpoint inhibition? <i>Paul Lorigan, Manchester, United Kingdom</i></p>	<p>10:00–10:05 Introductions</p>
<p>10:20–10:35 Does the future belong to personalised immunotherapy? <i>Patrick A. Ott, Boston, USA</i></p>	<p>10:05–10:20 Foundations of intralesional therapy for NMSC <i>Vishal A. Patel, Washington DC, USA</i></p>
<p>10:40–10:55 Role of targeted therapy in future therapy concepts. <i>Thomas Eigentler, Berlin, Germany</i></p>	<p>10:20–10:40 Advancements in intralesional therapy for NMSC <i>Michael R. Migden, Houston, USA</i></p>
	<p>10:40–11:00 Q&A</p>
<p>11:00–11:45 Coffee Break + Exhibition Visit + Poster Viewing</p>	

Room 3 (130 seats, Third Floor)

Room 4 (60 seats, First Floor)

10:00–11:00

Poster Discussion – Oral Communication III
Basal cell carcinoma and squamous cell carcinoma

*Chairs: Piergiacomo Calzavara-Pinton,
Brescia, Italy
Mirna Šitum, Zagreb, Croatia*

10:00–10:08

Line-field confocal optical coherence tomography for basal cell carcinoma: preliminary results of a diagnostic algorithm study validation
Dina Aktas, Brussels, Belgium

10:10–10:18

Risk of cutaneous squamous cell carcinoma local recurrence, metastasis, and disease-specific death in solid organ transplant recipients: a nationwide matched case-control study
Mathias Ørholt, Copenhagen, Denmark

10:20–10:28

Immunological deficiency in cutaneous squamous cell carcinoma of patients with recessive dystrophic epidermolysis bullosa
Angela Filoni, Lecce, Italy

10:30–10:38

Skin cancer risk in kidney transplant patients: analysis of EUSCAP Registry
Judith Lipski, Brussels, Belgium

10:40–10:48

Intralesional administration of L19IL2/L19TNF in difficult-to-treat BCC patients shows favorable safety profile and leads to complete remission of tumor lesions
Lisa Nadal, Siena, Italy

10:50–10:58

Optimal duration of cemiplimab therapy in advanced cutaneous squamous cell carcinoma
Emily Ruiz, Boston, USA

Saturday, April 22nd, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>11:45–12:15</p>	
<p>Keynote Lecture 7 <i>Chair: Pietro Quaglino, Turin, Italy</i></p> <p>Cutaneous lymphomas <i>Emmanuella Guenova, Lausanne, Switzerland</i></p>	
<p>12:15–12:45</p>	
<p>Keynote Lecture 8 <i>Chair: Veronique del Marmol, Brussels, Belgium</i></p> <p>Primary prevention of skin cancer: what the world can learn from Australia <i>David Whiteman, Brisbane, Australia</i></p>	
<p>12:45–13:30 Lunch Break + Exhibition Visit + Poster Viewing</p>	
<p>13:30–14:30</p>	
<p>Symposium 22 Challenging cases in skin cancer <i>Chairs: Matilda Bylaitė-Bučinskienė, Vilnius, Lithuania</i> <i>Ana-Maria Forsea, Bucharest, Romania</i></p>	
<p>13:30–13:42 Case 1 <i>Matilda Bylaitė-Bučinskienė, Vilnius, Lithuania</i></p>	
<p>13:45–13:57 Case 2 <i>Ana-Maria Forsea, Bucharest, Romania</i></p>	
<p>14:00–14:12 Case 3 <i>Monika Arenbergerova, Prague, Czech Republic</i></p>	
<p>14:15–14:27 Case 4 <i>Mahtab Samimi, Tours, France</i></p>	

Room 3 (130 seats, Third Floor)

Room 4 (60 seats, First Floor)

13:30–14:30

Poster Discussion – Oral Communication IV

Actinic keratosis and rare skin tumors

Chairs: Mauro Alaibac, Padova, Italy

Bohdan Lytvynenko, Kyiv, Ukraine

13:30–13:38

Incidence, local recurrence and metastasis of dermatofibrosarcoma protuberans: A nationwide cohort study of 40 years

Mathias Ørholt, Copenhagen, Denmark

13:40–13:48

Molecular profiling to guide treatment for eccrine carcinoma

Justine Cohen, Philadelphia, USA

13:50–13:58

Basal proliferation and acantholysis are histological high-risk factors for progression into invasive squamous cell carcinoma: a comparison study in solid organ transplant recipients and matched immunocompetent patients

Georgina Gilbert, Edinburgh, United Kingdom

Saturday, April 22nd, 2023

Room 1 (Auditorium, 700 seats, Ground Floor)	Room 2 (250 seats, Third Floor)
<p>14:30–15:30</p> <p>Symposium 23 Management of easy-to-treat basal and squamous cell carcinoma <i>Chairs: Catherine Harwood, London, United Kingdom</i> <i>Maria Concetta Fagnoli, L'Aquila, Italy</i></p>	<p>14:30–15:30</p> <p>Symposium 24 Management of rare malignant skin tumors <i>Chairs: Petr Arenberger, Prague, Czech Republic</i> <i>Judit Oláh, Szeged, Hungary</i></p>
<p>14:30–14:42 Diagnosing easy to treat keratinocyte carcinomas <i>Klara Mosterd, Maastricht, The Netherlands</i></p>	<p>14:30–14:42 Pitfalls in the diagnostics of rare skin malignancies <i>Petr Arenberger, Prague, Czech Republic</i></p>
<p>14:45–14:57 Current treatment pathways for easy to treat BCC and SCC <i>Maria Concetta Fagnoli, L'Aquila, Italy</i></p>	<p>14:45–14:57 Difficult to treat cases with rare sarcomas <i>Judit Oláh, Szeged, Hungary</i></p>
<p>15:00–15:12 What's new on medical treatment of keratinocyte cancers <i>Catherine Harwood, London, United Kingdom</i></p>	<p>15:00–15:12 Difficult to treat cases with rare adnexal tumours <i>Zsuzsanna Lengyel, Pécs, Hungary</i></p>
<p>15:15–15:27 What's new on destructive treatments of keratinocyte cancers <i>Merete Haedersdal, Copenhagen, Denmark</i></p>	<p>15:15–15:27 Rare tumors of anogenital area <i>Erika Varga, Szeged, Hungary</i></p>
<p>15:30–15:45 Closing Ceremony and Poster & Oral Communication Awards</p>	

Room 3 (130 seats, Third Floor)

Room 4 (60 seats, First Floor)

14:00–14:08

Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC)

Ikuko Hirai, Tokyo, Japan

14:10–14:18


Prevalence and determinants of actinic keratosis in Europe based on the Euromelanoma campaign

Gerardo Palmisano, Rome, Italy

14:20–14:28

Intralesional T-VEC in cutaneous B-cell lymphoma

Egle Ramelyte, Zurich, Switzerland



**SATELLITE
SYMPOSIA
AT A
GLANCE**

Room 1 (700 seats)	Room 2 (250 seats)	Room 3 (130 seats)	Room 4 (60 seats)	April 20, 2023
13:45–14:45 Satellite Symposium 1 Gold Sponsor Bristol Myers Squibb				
	17:30–18:00 Satellite Symposium 2 Silver Sponsor Pierre Fabre	17:30–18:30 Satellite Symposium 3 Bronze Sponsor Answers in CME*		

Room 1 (700 seats)	Room 2 (250 seats)	Room 3 (130 seats)	Room 4 (60 seats)	April 21, 2023
			08:00–09:00 Satellite Symposium 3a Further Sponsor Beiersdorf	
11:00–12:00 Satellite Symposium 1 Platinum Sponsor MSD				
12:30–13:30 Satellite Symposium 2 Platinum Sponsor Sanofi-Regeneron				
15:00–15:30 Satellite Symposium 4 Further Sponsor Philogen	15:00–16:00 Satellite Symposium 5 Bronze Sponsor Answers in CME*	15:00–16:00 Satellite Symposium 6 Bronze Sponsor Sun Pharma	15:00–15:45 Satellite Symposium 7 Bronze Sponsor Almirall	
15:30–16:00 Satellite Symposium 4a Silver Sponsor Novartis				
17:30–18:30 Satellite Symposium 8 Bronze Sponsor DAMAE Medical	17:30–18:15 Satellite Symposium 8a Further Sponsor NeraCare			

* This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Thursday, April 20th, 2023



Room 1 13:45–14:45

GOLD SPONSOR Satellite Symposium 1

Data and Debate: Optimal treatment selection for patients with metastatic melanoma

Chair: *Mike Postow, New York, USA*

- 13:45–13:50 Welcome and introduction
Mike Postow, New York, USA
- 13:50–14:10 Navigating first-line treatment choice in a changing landscape
Michele Del Vecchio, Milano, Italy
- 14:10–14:30 Sequencing scenarios for patients with *BRAF*-mutant melanoma
Christoph Hoeller, Vienna, Austria
- 14:30–14:45 Clinical challenges in the management of I-O-experienced patients
All faculty, moderated by *Mike Postow, New York, USA*



Room 2 17:30–18:00

SILVER SPONSOR Satellite Symposium 2

Spotlight on targeted therapies for advanced *BRAF*-mutant melanoma: Exploring evidence through real-world practice and digital applications

Chair: *Peter Mohr, Buxtehude, Germany*

- 17:30–17:33 Welcome and introduction
Peter Mohr, Buxtehude, Germany
- 17:33–17:43 Clinical conversations: How does real-world practice reflect our progress in advanced *BRAF*-mutant melanoma?
Edgar Pratas, Coimbra, Portugal
- 17:43–17:55 Exploring the Digital Age: How can we best support the patient's treatment journey?
Peter Mohr, Buxtehude, Germany
Edgar Pratas, Coimbra, Portugal
- 17:55–18:00 Audience Q&A, summary and conclusion
Peter Mohr, Buxtehude, Germany
Edgar Pratas, Coimbra, Portugal



Room 3 17:30–18:00

BRONZE SPONSOR Satellite Symposium 3

Advancing outcomes in surgically resectable cutaneous squamous cell carcinoma: Carving new paths forward with immunotherapies

Chairs and Speakers: *Axel Hauschild, Kiel, Germany*
Vishal Patel, Washington, D.C., USA

- 17:30–17:35 Welcome and introductions
- 17:35–17:45 A global need for improved outcomes in resectable cutaneous squamous cell carcinoma (CSCC): Can immunotherapies pave the way?
- 17:45–17:55 The road ahead for patients with resectable CSCC: Evaluating the efficacy of neoadjuvant immunotherapies
- 17:55–18:05 Expanding the margin of safety for neoadjuvant immunotherapies: Proactive strategies to maximize quality of life in patients with resectable CSCC
- 18:05–18:15 A global view on neoadjuvant treatment of resectable CSCC: Personalizing the approach to integrating immunotherapies into treatment plans
- 18:15–18:25 Questions
- 18:25–18:30 Take home learnings



Friday, April 21st, 2023



Room 4 08:00–09:00

FURTHER SPONSOR Satellite Symposium 3a

Eucerin Symposium – Meet the Experts

Actinic Keratosis & NMSC: Prevention, diagnosis and treatment. What's new?

Chair: *Ketty Peris, Rome, Italy*



Room 1 11:00–12:00

PLATINUM SPONSOR Satellite Symposium 1

Clinical decision making in melanoma: how to treat in 2023?

Chair: *Paolo Ascierto, Naples, Italy*

11:00–11:05 Welcome and introduction

Paolo Ascierto, Naples, Italy

11:05–11:15 Practice-changing advances in resected high-risk melanoma

Peter Mohr, Buxtehude, Germany

11:15–11:25 Advanced melanoma: How to treat in 2023?

Reinhard Dummer, Zurich, Switzerland

11:25–11:55 Case-based panel discussion

Faculty

11:55–12:00 Closing remarks

Paolo Ascierto, Naples, Italy

sanofi | **REGENERON**

Room 1 12:30–13:30

PLATINUM SPONSOR Satellite Symposium 2

Sanofi Regeneron Satellite Symposium Video Teaser

Emerging treatment paradigms in advanced BCC and CSCC

Chair: *Axel Hauschild, Kiel, Germany*

12:30–12:35 Welcome and Introductions

Axel Hauschild, Kiel, Germany

12:35–12:50 Current perspectives on treatment strategies for high-risk and advanced CSCC

Axel Hauschild, Kiel, Germany

12:50–13:05 Optimizing treatment options for advanced BCC

Ketty Peris, Rome, Italy

13:05–13:20 Future perspectives and treatment directions in NMSC

Reinhard Dummer, Zurich, Switzerland

13:20–13:30 Panel Discussion

All Faculty, moderated by Axel Hauschild, Kiel, Germany



Room 1 15:00–15:30

FURTHER SPONSOR Satellite Symposium 4

Innovative targeted therapies

Chairs: *Claus Garbe, Tuebingen, Germany*

Axel Hauschild, Kiel, Germany

15:00-15:05 Welcome

15:05-15:30 Innovative targeted therapies in oncology and beyond

Dario Neri, Siena Italy



Room 1 15:30–16:00

SILVER SPONSOR Satellite Symposium 4a

Life after therapy: Evolution of BRAF-mutant melanoma adjuvant treatment

Chair: *Axel Hauschild, Kiel, Germany*

15:30–15:35 Welcome and introduction

Axel Hauschild, Kiel, Germany

15:35–15:45 Evolution of adjuvant therapy: Improved outcomes and potential unmet needs

Axel Hauschild, Kiel, Germany

15:45–15:55 Current challenges in survival: What are the needs of melanoma survivors and how to address them?

Mario Mandalà, Perugia, Italy

15:55–16:00 Audience Q&A, summary and close

All speakers



Room 2 15:00–16:00

BRONZE SPONSOR Satellite Symposium 5

An evolution in care for advanced melanoma: Exploring the clinical implications of approved and emerging anti-LAG-3/PD-1 combinations

Chairs and speakers: *Vishal Patel, Washington, D.C., USA*

Dirk Schadendorf, Essen, Germany

15:00–15:05 Welcome and introductions

15:05–15:15 Expanding options, improved outcomes: Evaluating the evolving treatment paradigm for advanced melanoma

15:15–15:25 Updating the standards of care in advanced melanoma treatment: Evaluating the most recent data

15:25–15:35 Keeping patient needs in the forefront of advanced melanoma care: A proactive approach to safety management

15:35–15:45 Driving innovation through patient-centered care: A personalized approach to advanced melanoma treatment

15:45–15:55 Questions

15:55–16:00 Take home learnings



Room 3 15:00–16:00

BRONZE SPONSOR Satellite Symposium 6

Long Term Management Strategy For LaBCC

A practical walk-through on the management of the therapy with Sonidegib for the treatment of LaBCC

Chair: *Ketty Peris, Rome, Italy*

- 15.00–15.05 Welcome & introduction
Ketty Peris, Rome, Italy
- 15.05–15.20 First Line systemic treatment of LaBCC
Nicole Basset-Seguín, Paris, France
- 15.20–15.35 Optimal management of HHI therapy
Susana Puig, Barcelona, Spain
- 15.35–15.50 LaBCC treatment algorithm in practice
Ketty Peris, Rome, Italy
- 15.50–16.00 Discussion & Closure
All, Ketty Peris, Rome, Italy



Room 4 15:00–15:45

BRONZE SPONSOR Satellite Symposium 7

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

Chair: *Thomas Dirschka, Germany*

- 15:00-15:10 Doctor, is it cancer?
Thomas Dirschka, Germany
- 15:10-15:25 Doctor, should I expect any side effects?
Maria Concetta Fagnoli, Italy
- 15:25-15:40 Doctor, am I cured?
Aram Boda, Spain
- 15:40-15:45 Q&A



Room 1 17:30–18:30

BRONZE SPONSOR Satellite Symposium 8

LC-OCT, the new imaging frontier in skin cancer?

Chair: *Josep Malvehy, Barcelona, Spain*

- 17:30–17:45 Diagnostic performance of LC-OCT for BCC: new data from prospective and meta analytic studies. Patient management
Mariano Suppa, Brussels, Belgium
- 17:50–18:05 The role of LC-OCT in BCC margin delineation – the one-stop-shop approach
Julia Welzel, Augsburg, Germany
- 18:10–18:25 LC-OCT of melanocytic lesions – practical steps for routine diagnosis of equivocal melanocytic lesions
Javiera Perez-Anker, Barcelona, Spain

Room 2 17:30–18:15

FURTHER SPONSOR Satellite Symposium 8a

Identifying the killers among low risk melanomas

- 17:30–17:35 Welcome & introduction
Dirk Schadendorf, Essen, Germany
- 17:35–18:00 Immunoprint data
Axel Hauschild, Kiel, Germany
Teresa Amaral, Lisbon, Portugal
- 18:00–18:10 Q&A
Axel Hauschild, Kiel, Germany
Dirk Schadendorf, Essen, Germany
- 18:10–18:15 Closing remarks
Claus Garbe, Tuebingen, Germany


SPONSORS

PLATINUM SPONSORS



sanofi | **REGENERON**

GOLD SPONSOR



SILVER SPONSORS



BRONZE SPONSORS



DAMAE MEDICAL

IMMUNOCORE



MERCK




SPONSORS AND EXHIBITORS



CONGRESS APP SPONSOR

The EADO 2023 Congress App is kindly supported by  

SPONSORED POSTER AWARDS

The research award is kindly supported by 

COMPANY PROFILES

PLATINUM SPONSORS



At **MSD**, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on **twitter**, **linkedin** and **YouTube**.

sanofi | **REGENERON**

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

For more information, please visit www.Regeneron.com or follow **@Regeneron** on Twitter.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

For more information, please visit www.Sanofi.com.

Sanofi is listed on Euronext: SAN and NASDAQ: SNY

GOLD SPONSOR



Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients' lives through science.

SILVER SPONSOR



Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

Find out more at www.novartis.com



Pierre Fabre

Pierre Fabre is a French healthcare company with over 35-years of experience in innovation, development, manufacturing and commercialization in oncology. Its portfolio includes several medical franchises and international brands, namely Pierre Fabre Oncology, Pierre Fabre Dermatology, Pierre Fabre Health Care, Eau Thermale Avène, Klorane, René Furterer, A-Derma, Darrow, Glytone, Naturactive and Pierre Fabre Oral Care. The company has declared oncology its top priority in medical care R&D and commercialization, focusing on targeted therapies and biotherapies. Its portfolio covers oncology (colorectal, breast, lung cancers, melanoma and pre-cancerous conditions like actinic keratosis), hematology and rare diseases.

Clinical decision- making in melanoma: How to treat in 2023?

Auditorium della Tecnica
Rome, Italy

Friday, 21 April 2023

11:00 - 12:00 (CET)

Congress symposium sponsored by MSD

Chair: Paolo Ascierto (Italy)

Chair



Paolo Ascierto

Director of Department
of Skin Cancers, Cancer
Immunotherapy and
Development Therapeutics
Melanoma Unit
National Tumour Institute
"Fondazione G. Pascale"
Naples, Italy

Faculty



Reinhard Dummer

Professor of the University
of Zurich and Vice-Chairman
Department of Dermatology
in the University Hospital
Zürich, Switzerland



Peter Mohr

Chief Physician
Department of Dermatology
Elbe Klinikum Buxtehude
Head of Skin Cancer
Center Buxtehude
Buxtehude, Germany

Agenda

11:00 - 11:05	Introduction Paolo Ascierto
11:05 - 11:15	Practice-changing advances in resected high-risk melanoma Peter Mohr
11:15 - 11:25	Case-based panel discussion Peter Mohr
11:25 - 11:35	Advanced melanoma: How to treat in 2023? Reinhard Dummer
11:35 - 11:45	Case-based panel discussion Reinhard Dummer
11:45 - 11:55	Case-based panel discussion Paolo Ascierto
11:55 - 12:00	Closing remarks Paolo Ascierto

Emerging Treatment Paradigms in Advanced BCC and CSCC

Friday, 21 April 2023 | 12:30–13:30 CET

Auditorium della Tecnica, Room 1, Ground Floor,
Viale Umberto Tupini, 65, 00144 Rome, Italy



Professor Axel Hauschild

University Hospital
Schleswig-Holstein
Campus Kiel, Germany



Professor Ketty Peris

Catholic University of the
Sacred Heart, Department
of Dermatology, Rome, Italy



Professor Reinhard Dummer

University Hospital of Zürich
Zürich, Switzerland

12:30–12:35

Welcome and Introductions

Prof. Axel Hauschild (Chair, Germany)

12:35–12:50

Current Perspectives on Treatment Strategies for High-risk and Advanced CSCC

Prof. Axel Hauschild (Germany)

12:50–13:05

Optimizing Treatment Options for Advanced BCC

Prof. Ketty Peris (Italy)

13:05–13:20

Future Perspectives and Treatment Directions in NMSC

Prof. Reinhard Dummer (Switzerland)

13:20–13:30


Panel Discussion

All Faculty, Moderated by Prof. Axel Hauschild
(Chair, Germany)



Transforming patients' lives through science™

We are in the business of breakthroughs—the kind that transform patients' lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we'll never give up our search for more hope, for more people, around the world.



We're proud to support the 19th EADO Congress 2023



Life after therapy: Evolution of *BRAF*-mutant melanoma adjuvant treatment

21 April 2023 | 15:30-16:00 CEST | Room 1: Auditorium



Faculty



Prof. Axel Hauschild (Chair)
University Hospital Schleswig-Holstein
Kiel, Germany



Prof. Mario Mandalà
Università degli Studi di Perugia
Perugia, Italy

This satellite symposium is funded by Novartis Pharma AG.
This material has been developed for non-US healthcare professionals only.

Novartis Pharma AG,
CH-4002 Basel, Switzerland

© 2023 Novartis

267209 | March 2023

10230153000

Program

Welcome and Introduction

Axel Hauschild

Evolution of adjuvant therapy: Improved outcomes and potential unmet needs

Axel Hauschild

Current challenges in survival: What are the needs of melanoma survivors and how to address them?

Mario Mandalà

Audience Q&A, summary and close

All speakers



EADO 2023 SATELLITE SYMPOSIUM

Spotlight on targeted therapies for advanced *BRAF*-mutant melanoma: Exploring evidence through real-world practice and digital applications

THURSDAY, 20 APRIL 2023 | 17:30-18:00 CEST

Live: Room 2 (third floor) | Auditorium della Tecnica | Rome, Italy
Virtual: EADO Virtual Events Platform

MEET THE EXPERTS



Chair: Dr Peter Mohr
Elbe Kliniken Buxtehude
Buxtehude, Germany



Dr Edgar Pratas
Centro Hospitalar e
Universitário de Coimbra (CHUC)
Coimbra, Portugal



Sun Pharma Symposium

Friday 21 April 2023, 15:00 – 16:00

Room 3
Satellite Symposium 6

LONG TERM MANAGEMENT STRATEGY FOR IaBCC:

explained

A practical walk-through on the management of the therapy
with Sonidegib for the treatment of IaBCC

Faculty



Prof. Ketty Peris
Rome, Italy (Chair)



Prof. Nicole Basset-Seguin
Paris, France



Prof. Susana Puig
Barcelona, Spain

19th EADO Congress
April 20th – 22nd 2023, Rome, Italy



Don't miss out our Satellite Symposium

Doctor, is it cancer? Main Actinic Keratosis patients' concerns and therapeutic approaches



Chairman:
Prof. Thomas Dirschka
(Germany)
Doctor, is it cancer?



Prof. Maria Concetta Fagnoli
(Italy)
Doctor, should I expect any side effects?



Dr. Aram Boada
(Spain)
Doctor, am I cured?

Why to attend this Symposium? Three European medical experts will discuss some of the latest clinically-relevant advances in AK, including potential new biomarkers, a practical evidence-based update on choosing the right therapy for the right patient, and the importance of patient reported outcomes.

Friday **April 21st**

Meeting room 4. First floor **15:00 pm**
Satellite Symposium 7



BRONZE SPONSOR

This session has been organized and funded by Almirall S.A. and may include promotional contents. Almirall symposium, booth and congress website are intended for HCP holding a Congress registration. Note that the symposium will be recorded.



Our mission is to radically improve outcomes for patients

with cancer, infectious diseases, and autoimmune conditions by pioneering and delivering transformative medicines

NOW RECRUITING PATIENTS IN MULTIPLE CLINICAL TRIALS

More information about what we do at immunocore.com



IMMUNOCORE



Replimune is advancing a pipeline of tumor-directed oncolytic immunotherapies (TDOI) designed to change the landscape of cancer for good

Visit Booth 16 to learn more about this exciting cancer platform



Merlin CE IVD

NOW AVAILABLE

Helps identify patients who may forgo SLNB

Booth #18



First model integrating clinic and pathologic features with gene expression information (CP-GEP)



Performed directly from the primary biopsy tissue



Macrodissection not required



Or visit our website:
merlinmelanomatest.com





DO YOU SEE IT? LOOK AGAIN

Blastic Plasmacytoid Dendritic Cell Neoplasm.

A very rare, clinically aggressive hematologic malignancy which often goes misdiagnosed.¹

If something doesn't feel right, speak with your clinical team.




**Raise your
BPDCN
awareness**



Stemline®
A Menarini Group Company

1. Sullivan JM and Rizzieri DA. *Hematology Am Soc Hematol Educ Prog* 2016; 2016(1):16–23.

DURABLE RESPONSE TO MERKEL CELL CARCINOMA¹⁻³



BAVENCIO® (AVELUMAB) IS THE FIRST IMMUNOTHERAPY APPROVED IN EUROPE FOR ADULT PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA.⁴

BAVENCIO® (avelumab) is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma.¹ Regulatory approval varies from country to country. Please check your local label for country-specific information.

Avelumab is associated with immune-related adverse reactions. In the JAVELIN Merkel 200 (EMR100070-003), the most common Grade ≥ 3 adverse reactions were anemia (5.6%), hypertension (3.9%), hyponatremia (3.6%), dyspnea (3.5%), and abdominal pain (2.6%).¹

Please [click here](#) for the Summary of Product Characteristics.

1. BAVENCIO® Riassunto delle Caratteristiche del Prodotto, December 2022. 2. D'Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. *J Immunother Cancer*. 2021;9(7):e002646. 3. D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. *ESMO Open*. 2021;6(6):100290. 4. Spada F, Bossi P, Caraco C, et al. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. *Journal for ImmunoTherapy of Cancer* 2022;10:e004742. doi:10.1136/jitc-2022-004742.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of SmPC for how to report adverse reactions.

Bavencio 20mg/mL concentrato per soluzione per infusione

Rimborsato SSN Classe H – OSP

In monoterapia per il trattamento di pazienti adulti affetti da carcinoma a cellule di Merkel (Merkel Cell Carcinoma, MCC) metastatico; in monoterapia per il trattamento di mantenimento di prima linea di pazienti adulti affetti da carcinoma uroteliale (urothelial carcinoma, UC) localmente avanzato o metastatico senza progressione dopo chemioterapia a base di platino

Non rimborsato SSN Classe C – OSP

In associazione con axitinib per il trattamento di prima linea di pazienti adulti affetti da carcinoma a cellule renali (renal cell carcinoma, RCC) avanzato

1 flaconcino 10 mL (200mg)

A.I.C. n. 045613015/E

Prezzo al pubblico vigente €1.626,56

IT-AVEMCC-00041. Pubblicità rivolta ai Medici – Depositata in AIFA il 03/04/2023. Vietata la distribuzione / Esposizione al Pubblico.

MERCK

Pfizer

BAVENCIO®
avelumab 20 mg/mL
Concentrate for solution for infusion

> Empowering people, informing care decisions

Driven by a shared purpose, we are transforming the diagnosis and treatment of dermatological cancers, enabling more precise testing for better informed decisions for cutaneous melanoma and squamous cell carcinoma.

Decision Dx
▶ Melanoma

Decision Dx
▶ SCC

MyPath
▶ Melanoma



castletestinfo.com



**FUTURE
MEETINGS**



Save the Date

June 22nd–23rd, 2023

**Munich, Germany
Hilton Hotel Munich Park**

www.postchicago.org

13th European Post-Chicago Melanoma/Skin Cancer Meeting



Melanoma
World Society
MWS

Congress Presidents
Axel Hauschild, Kiel, Germany
Claus Garbe, Tuebingen, Germany



20TH

**EADO
CONGRESS
2024**

APRIL 4th–6th, 2024

PARIS, FRANCE
Versailles Palais des Congrès

SAVE THE DATE





The EUROPEAN CERTIFICATION for MEDICAL TUMOR THERAPY in DERMATO-ONCOLOGY:

Register Now for the 2024 Examination!

The professional competence in conducting systemic therapy for skin cancers is certified by the **European Certificate for Medical Tumor Therapy in Dermato-Oncology** awarded by **EADO** in collaboration with **UEMS**.

The Certification is acquired upon successfully passing the **EADO Examination**, which will be held on Saturday, January 13th, 2024 during the 12th European School of Dermato-Oncology, Berlin, Germany.

The Examination is open for Dermatology specialists and final year residents with clinical experience in the systemic treatment of skin cancers.

Deadline for application: December 1st, 2023

Please visit the www.eado.org website to keep informed about the latest updates and feel free to contact the EADO office at info@eado.org for any query.

EADO - European Association of Dermato-Oncology. An organization dedicated to promote, coordinate and improve clinical and laboratory research in skin cancer. A non-profit organization registered in Switzerland, Max-Högger-Strasse 6, 8048 Zurich.



Course Directors

Véronique Del Marmol, Brussels, Belgium
Claus Garbe, Tuebingen, Germany
Axel Hauschild, Kiel, Germany
Giovanni Pellacani, Modena, Italy

**12th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY
UPDATE ON CUTANEOUS ONCOLOGY
JANUARY 12th-13th, 2024
NOVOTEL BERLIN AM TIERGARTEN
BERLIN, GERMANY**

SAVE
THE
DATE

3.-5. APRIL 2025 **11th WORLD CONGRESS OF MELANOMA AND 21st EADO CONGRESS**

Megaron Athens
International Conference
Centre
Athens, Greece

SAVE
THE
DATE



worldmelanoma2025.com